SCHEMBL4745812

SCHEMBL4745812

Cc1ccc2c(c1)c(-c1ccc3ccccc3c1)cc1c3ccc(C)c4c3c(cc21)-c1ncccc1-4

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.34
HTR2B P41595 1/20 0.34
HTR5A P47898 1/20 0.34
ADORA2A P29274 1/20 0.33
ADORA1 P30542 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
HPGD P15428 1/20 0.33
TSHR P16473 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HSD17B10 Q99714 1/20 0.33
DHFR P00374 1/20 0.33
CYP2A6 P11509 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
DHODH Q02127 1/20 0.32
PIK3CD O00329 1/20 0.32
ABL1 P00519 1/20 0.32
EGFR P00533 1/20 0.32
HCK P08631 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4746389 0.97 DHODH (0.34) ALDH1A1HPGDHSD17B10DHODHABL1
SCHEMBL4746387 0.96 DHODH (0.33) ALDH1A1HPGDHSD17B10DHODHKDM4E
SCHEMBL4746019 0.91 ALDH1A1 (0.44) ALDH1A1ADORA2ACYP1A2DHODHCCR1
SCHEMBL4746018 0.91 ALDH1A1 (0.44) ALDH1A1ADORA2AADORA1DHODHPIK3CD
SCHEMBL4746339 0.90 DHODH (0.36) ALDH1A1SMN1; SMN2TDP1DHODHKDM4E
SCHEMBL4746099 0.90 ABL1 (0.36) ALDH1A1SMN1; SMN2PIK3CDABL1EGFR
SCHEMBL4746063 0.90 PIK3CD (0.38) ALDH1A1SMN1; SMN2PIK3CDABL1EGFR
SCHEMBL4746317 0.89 DHODH (0.35) ALDH1A1DHODHKDM4EBCHE
SCHEMBL4745945 0.88 HPRT1 (0.37) ALDH1A1CYP1A2CYP3A4SMN1; SMN2CYP2A6
SCHEMBL4745792 0.88 BCHE (0.40) ALDH1A1HPGDSMN1; SMN2DHODHKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE NR2E3, OR51E2, AZI2 ALDH1A1 179/4885HTR2B 434/4885HTR5A 613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.